Los Angeles Capital Management LLC decreased its stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 8.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 54,257 shares of the company’s stock after selling 5,120 shares during the period. Los Angeles Capital Management LLC’s holdings in Black Diamond Therapeutics were worth $459,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in BDTX. Advisor Group Holdings Inc. lifted its holdings in shares of Black Diamond Therapeutics by 420.6% in the 2nd quarter. Advisor Group Holdings Inc. now owns 3,280 shares of the company’s stock worth $41,000 after purchasing an additional 2,650 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Black Diamond Therapeutics by 65.6% in the 2nd quarter. Rhumbline Advisers now owns 30,318 shares of the company’s stock worth $370,000 after purchasing an additional 12,012 shares during the last quarter. Swiss National Bank lifted its holdings in shares of Black Diamond Therapeutics by 95.1% in the 2nd quarter. Swiss National Bank now owns 47,600 shares of the company’s stock worth $580,000 after purchasing an additional 23,200 shares during the last quarter. Nisa Investment Advisors LLC bought a new stake in Black Diamond Therapeutics during the 2nd quarter valued at $51,000. Finally, Virtus ETF Advisers LLC raised its stake in Black Diamond Therapeutics by 99.4% during the 2nd quarter. Virtus ETF Advisers LLC now owns 17,462 shares of the company’s stock valued at $213,000 after acquiring an additional 8,706 shares in the last quarter. 66.54% of the stock is currently owned by institutional investors and hedge funds.
BDTX opened at $4.24 on Friday. The company has a market capitalization of $153.61 million, a PE ratio of -1.25 and a beta of 1.46. The stock’s fifty day moving average is $6.02 and its 200-day moving average is $8.24. Black Diamond Therapeutics, Inc. has a one year low of $3.99 and a one year high of $29.65.
Several analysts have weighed in on BDTX shares. Zacks Investment Research raised Black Diamond Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 19th. Stifel Nicolaus began coverage on Black Diamond Therapeutics in a research note on Wednesday, September 29th. They issued a “hold” rating and a $10.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $33.80.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc, a biotechnology company, discover and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an irreversible small molecule inhibitor that is designed to block the function of family of oncogenic proteins defined by driver mutations across a range of tumor types, and which affect the epidermal growth factor receptor (EGFR), the tyrosine-protein kinase, or human epidermal growth factor receptor 2.
Want to see what other hedge funds are holding BDTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX).
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.